Researchers at Mount Sinai’s Corinne Goldsmith Dickinson Center for Multiple Sclerosis played a key role in developing a potential breakthrough treatment for progressive multiple sclerosis (MS), according to findings that were presented in October 2015 at the meeting of the European Committee for Treatment and Research in MS in Barcelona, Spain. The Center also recently received funding to lead a new international coalition tasked with developing a strategy for diagnosing progressive MS earlier. Both efforts further strengthen Mount Sinai’s reputation as a worldwide leader in MS research. Read more
Two new Big Data analysis tools that help pinpoint specific genes that are actively involved in disease progression were recently made available to the public by scientists in the Multiscale Network Modeling Laboratory at the Icahn School of Medicine at Mount Sinai.
The team, led by Bin Zhang, PhD, Associate Professor in the Department of Genetics and Genomic Sciences, published the pair of algorithm-based tools online in November 2015 in PLoS Computational Biology and in Scientific Reports, a Nature publication. The open-source tools are available to all researchers who wish to gain a better understanding of disease mechanisms in order to develop more effective drugs and create individualized treatments. Read more
In its first full year of operation, the Mount Sinai Genetic Testing Laboratory in Branford, Connecticut, has become an integral part of the Mount Sinai Health System’s efforts to better diagnose and treat disease.
The 16,400-square-foot facility, located 85 miles from New York City, has the high-throughput equipment to sequence thousands of samples monthly to uncover variations in DNA that code for Alzheimer’s and coronary disease, and cancer, among other diseases. Read more
Advanced-stage cancer patients who received palliative care required shorter durations of radiation treatment and had shorter hospital stays, according to a recent study at the Icahn School of Medicine at Mount Sinai.
“Radiation therapy is very effective at relieving pain, but the standard two weeks of treatment may be too long or burdensome for some patients, given the state of their illnesses,” says the study’s senior author, Kavita Dharmarajan, MD, M.Sc, Assistant Professor of Radiation Oncology, and Geriatrics and Palliative Medicine, at the Icahn School of Medicine at Mount Sinai. “We showed that shorter course treatments can be equally, if not more, effective, especially when combined with other forms of therapy that put patients first, and not the tumor.” Read more
Individuals whose siblings have bipolar disorder are at high risk for developing mood disorders themselves. However, siblings who remain psychiatrically healthy may have a natural ability to rewire their brains that compensates for their genetic risk. These findings, led by Sophia Frangou, MD, PhD, Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai, were published in the January 5, 2016, issue of Translational Psychiatry. Read more
After carefully analyzing the electronic health records (EHRs) of 11,000 patients, investigators at the Icahn School of Medicine at Mount Sinai have discovered three potential new subtypes of type 2 diabetes.
The discovery, led by Joel Dudley, PhD, Director of Biomedical Informatics at the Icahn School of Medicine, highlights the power of new technology and the promise of precision medicine, as the Mount Sinai Health System ushers in the use of Big Data in discovering, treating, and preventing disease. The results of the study were published in Science Translational Medicine in October, 2015. Read more
Researchers at The Tisch Cancer Institute have uncovered an intriguing mechanism that may help explain why radiation therapy eradicates cancerous tumors in some patients but not in others.
Their study, reported in the September 7, 2015, issue of Nature Immunology, examined how special skin immune cells, known as Langerhans cells, perform in mice models of melanoma. Read more
The Mount Sinai Genetic Testing Lab, housed in the Department of Genetics and Genomic Sciences and led by Executive Director Lisa Edelmann, worked closely with clinical geneticists who see patients for rare diseases, as well as the bioinformatics team at the Icahn Institute for Genomics and Multiscale Biology at Mount Sinai, to create a line of new tests that help inform couples of their risk of having a child with a genetic disorder. Read more
An exciting development in birth defects research emerged in 2015! In 2013, Gabriella Miller, a young girl dying from cancer, called upon the U.S. Congress for “less talking, more doing…We need action.” This stimulated Congress to pass the Gabriella Miller Kids First Research Act in 2014, which authorized $12.6 million/year for 10 years toward pediatric research. In implementing this mandate, the National Institutes of Health (NIH) decided to use the 2015 funds for performing whole genome sequencing (WGS) for certain childhood cancers and, of relevance here, for structural birth defects. Read more
Joseph D. Buxbaum, PhD, a pioneering researcher in the field of autism, recently was elected to the National Academy of Medicine, considered one of the highest honors in medicine. New members are elected annually by current active members through a selective process that recognizes individuals who have made major contributions to advance medical sciences, health care, and public health.
A world-renowned molecular geneticist and neurobiologist, Dr. Buxbaum is Professor and Vice Chair for Research in the Department of Psychiatry, and Director of the Seaver Autism Center for Research and Treatment at Icahn School of Medicine at Mount Sinai. He is also Professor of Neuroscience, and Genetics and Genomic Sciences, and the G. Harold and Leila Y. Mathers Research Professor of Geriatrics and Adult Development. Read more